Efficacy and safety of a new immunoglobulin G product, Gammaplex(®), in primary immunodeficiency diseases.

@article{Moy2010EfficacyAS,
  title={Efficacy and safety of a new immunoglobulin G product, Gammaplex(®), in primary immunodeficiency diseases.},
  author={James N. Moy and Andrew M. Scharenberg and Mark R. Stein and Daniel Suez and Rebecca Roberts and Robin J Levy and Mark Ballow and Mary Beth Fasano and Clive H. Dash and Samantha J. Leach},
  journal={Clinical and experimental immunology},
  year={2010},
  volume={162 3},
  pages={510-5}
}
This open-label multi-centre study evaluated a new intravenous immunoglobulin, Gammaplex®, in the treatment of 50 patients with primary immunodeficiency and significant hypogammglobulinaemia. Patients treated previously with other intravenous immunoglobulins received Gammaplex® on their same infusion schedule for 1 year; 22 were on a 21-day and 28 on a 28-day regimen (300-800 mg/kg/infusion). There were no serious, acute bacterial infections, whereas six subjects (12·0%) had at least one such… CONTINUE READING